• Cephalosporins
• Carbapenems
• Monobactams
• Tetracyclines
• Nitroimidazoles
• Fluorquinolones
• Glycopeptides
• Antimycobacterials
• Antimycotics
• Other groups
• Polypeptides
• Vilimyxin

VILIMYXIN^®

• Complete drug information
  
• Antimicrobial spectrum
  

VILIMYXIN^® for Injection is one of a group of basic polypeptide antibiotics derived from B. polymyxa. VILIMYXIN^® is the sulfate salt of Polymyxins B1 and B2. VILIMYXIN^® has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of bacterial cell wall membranes. All gram-positive bacteria, fungi, and the gram-negative cocci, N. gonorrhoeae and N. meningitidis, are resistant. VILIMYXIN^® is not absorbed from the normal alimentary tract.

Clinical particulars:
VILIMYXIN^® demonstrates efficacy against infections caused by polyresistant gram-negative bacteria. Due to excellent activity against a wide range of gram-negative microorganisms (incl. Pseudomonas aeruginosa and Acinetobacter baumanii) it uses as a drug of choice for the treatment of the following infections caused by susceptible strains of Pseudomonas aeruginosa:

• infections of the urinary tract
• respiratory tract infections (incl. nosocomial pneumonia)
• meningitis
• bloodstream infection
• skin and soft tissue infections and infection of burn wound

Vilimyxin^® may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.
Vilimyxin^® may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:

• Acinetobacter spp.
• H influenzae, specifically meningeal infections.
• Escherichia coli, specifically urinary tract infections.
• Aerobacter aerogenes, specifically bacteremia.
• Klebsiella pneumoniae, specifically bacteremia.

NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.
Vilimyxin^® may use orally in the treatmaent of infections of alimentary tract caused gram-negative enteropathogenic strains of Enterobacteriaceae and for selective decontamination of GIT.



Pharmaceutical form: powder, for solution. Each vial contains Polymyxin B Sulfate equivalent to 250,000 r 500,000 polymyxin B units for parenteral or ophthalmic administration. Each milligram of pure polymyxin B base is equivalent to 10,000 units of polymyxin B and each microgram of pure polymyxin B base is equivalent to 10 units of polymyxin B.